NY-BEHAVOX
2.6.2020 14:02:13 CEST | Business Wire | Press release
Behavox , which provides the world’s only AI-based end-to-end data operating platform that enables enterprises to aggregate, analyze, and act on their entire organization's data, today announced that Danske Bank A/S , Denmark’s largest, full-service bank, has selected Behavox as its platform for electronic and audio communication compliance supervision.
As Behavox’s momentum in the finance sector continues to grow globally, Danske Bank represents its latest customer win in Europe. Danske Bank’s decision to select Behavox stems from the banking giant’s strategy to grow its business on the back of advanced data analytics – analytics that will help Danske Bank become faster, smarter, and more agile in supporting hundreds of branch sites and millions of clients throughout the Nordics.
According to Simon Kingsbury, Executive Vice President at Danske Bank, the use of effective data analytics to strengthen regulatory compliance controls is part of the wider efforts to modernize banking. Compliance efforts must be executed quickly, efficiently, and intelligently. To achieve greater agility and speed, particularly in a macroeconomic environment with increasingly distributed work environments, Mr. Kingsbury said Danske Bank is using Behavox to establish compliance operations that are fueled by cutting-edge artificial intelligence and machine learning. The Behavox Compliance solution’s AI and ML capabilities provide powerful data analytics to help Danske Bank identify immediate actions for ensuring regulatory compliance.
“At Danske Bank, compliance is not a checkbox,” said Mr. Kingsbury. “It is an integral part of our strategy in a competitive and demanding regulatory environment.”
Behavox supports financial regulatory compliance requirements for Dodd-Frank, MAR, FCPA, SMR, and MiFID II. Its solutions meet the requirements of the most demanding global regulators, such as FINRA, CFTC, and FCA. After conducting extensive due diligence, Mr. Kingsbury and the Danske Bank team selected Behavox because of its performance, the ability to deploy quickly, and key functional benefits.
“Danske Bank is our latest European customer with a vision to enhance risk management and compliance through agile SaaS-based operations. They understand the value of SaaS, AI, and ML working together,” Behavox Founder and CEO Erkin Adylov said. “As the only vendor who can enable enterprises to aggregate, analyze, and act on data to maintain regulatory compliance, we are committed to helping Danske and other customers uphold their risk management commitments.”
About Behavox Ltd.
Behavox is the leading, end-to-end Data Operating Platform that enables organizations to aggregate, analyze and act on their internal data. As a high-growth technology company, our mission is to organize and make useful all communications data on Earth. Through advanced analytics and machine learning, Behavox is your organization’s single-entry point for internal data.
Behavox, founded in 2014, is headquartered in New York City, with offices in London, Singapore and Montréal. For more information visit here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom